This file is part of IDEAS, which uses RePEc data


[ Papers | Articles | Software | Books | Chapters | Authors | Institutions | JEL Classification | NEP reports | Search | New papers by email | Author registration | Rankings | Volunteers | FAQ | Blog | Help! ]

Global Competitiveness in Pharmaceuticals: A European Perspective

Author info | Abstract | Publisher info | Download info | Related research | Statistics
Author Info
Gambardella, Alfonso
Orsenigo, Luigi
Pammolli, Fabio

Additional information is available for the following registered author(s):

Abstract

The report examines the competitive position of the European pharmaceutical companies and industries, and compares them with the pharmaceutical companies and industries in other parts of the world, particularly the US. Over the last two decades, the industry has experienced some important structural changes, mainly driven by technological and institutional shocks that have affected all the stages of its value chain. In turn, this has led to changes in firms' organisation and in market structure, within domestic markets, regionally, and globally. The main finding of the report is that the European industry has indeed been losing competitiveness as compared to the USA, although there are large differences and trends across European countries. As a whole, Europe is lagging behind in its ability to generate, organise, and sustain innovation processes that are increasingly expensive and organisationally complex. In fact, one conclusion of the report is that the relative position of the US as a locus of innovation in pharmaceuticals has increased over the past decade compared to Europe. All in all, the report claims that the competitiveness of the European pharmaceutical industry is negatively affected by the persistence of insufficient degrees of competition and institutional integration, still centred on domestic and fragmented health care and research systems. Four sets of variables have been found to be relevant as sources of competitiveness and growth in pharmaceuticals: 1) The size and the structure of the biomedical education and research systems; 2) Some basic institutions governing labor markets for skilled researchers and managers, as well as corporate governance and finance; 3) Intellectual property rights and patent law; 4) The institutional settings in the regulation of health care systems and, moreover, the nature and intensity of competition on the final market. The data analysed in this report come from OECD, Eurostat, the European Patent Office, IMS Health and PHID (PHarmaceutical Industry Database) at the University of Siena.

Download Info
To download:

If you experience problems downloading a file, check if you have the proper application to view it first. Information about this may be contained in the File-Format links below. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.

File URL: http://mpra.ub.uni-muenchen.de/15965/
File Format:
File Function:
Download Restriction: no

Publisher Info
Paper provided by University Library of Munich, Germany in its series MPRA Paper with number 15965.

Download reference. The following formats are available: HTML (with abstract), plain text (with abstract), BibTeX, RIS (EndNote, RefMan, ProCite), ReDIF
Length:
Date of creation: 01 Nov 2000
Date of revision:
Handle: RePEc:pra:mprapa:15965

Contact details of provider:
Postal: Schackstr. 4, D-80539 Munich, Germany
Phone: +49-(0)89-2180-2219
Fax: +49-(0)89-2180-3900
Web page: http://mpra.ub.uni-muenchen.de
More information through EDIRC

For technical questions regarding this item, or to correct its listing, contact: (Ekkehart Schlicht).

Related research
Keywords: Pharmaceutical Industry; R&D; Innovation; Competitiveness;

Other versions of this item:

Find related papers by JEL classification:
L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology
L16 - Industrial Organization - - Market Structure, Firm Strategy, and Market Performance - - - Industrial Organization and Macroeconomics; Macroeconomic Industrial Structure
D23 - Microeconomics - - Production and Organizations - - - Organizational Behavior; Transaction Costs; Property Rights
O32 - Economic Development, Technological Change, and Growth - - Technological Change - - - Management of Technological Innovation and R&D
D24 - Microeconomics - - Production and Organizations - - - Production; Capital and Total Factor Productivity; Capacity
O31 - Economic Development, Technological Change, and Growth - - Technological Change - - - Innovation and Invention: Processes and Incentives

References listed on IDEAS
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:

  1. Griliches, Zvi, 1990. "Patent Statistics as Economic Indicators: A Survey," Journal of Economic Literature, American Economic Association, vol. 28(4), pages 1661-1707, December. [Downloadable!] (restricted)
    Other versions:
  2. Jaffe, Adam B & Trajtenberg, Manuel & Henderson, Rebecca, 1993. "Geographic Localization of Knowledge Spillovers as Evidenced by Patent Citations," The Quarterly Journal of Economics, MIT Press, vol. 108(3), pages 577-98, August. [Downloadable!] (restricted)
    Other versions:
  3. repec:fth:harver:1473 is not listed on IDEAS
  4. Merges, Robert P. & Nelson, Richard R., 1994. "On limiting or encouraging rivalry in technical progress: The effect of patent scope decisions," Journal of Economic Behavior & Organization, Elsevier, vol. 25(1), pages 1-24, September. [Downloadable!] (restricted)
  5. S. Jacobzone, 2000. "Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals," OECD Labour Market and Social Policy Occasional Papers 40, OECD, Directorate for Employment, Labour and Social Affairs. [Downloadable!]
  6. Arora, Ashish & Gambardella, Alfonso, 1994. "The changing technology of technological change: general and abstract knowledge and the division of innovative labour," Research Policy, Elsevier, vol. 23(5), pages 523-532, September. [Downloadable!] (restricted)
  7. Arora, Ashish & Gambardella, Alfonso & Pammolli, Fabio & Riccaboni, Massimo, 2000. "The Nature and the Extent of the Market for Technology in Biopharmaceuticals," MPRA Paper 15977, University Library of Munich, Germany. [Downloadable!]
  8. Mowery, David C., 1998. "The changing structure of the US national innovation system: implications for international conflict and cooperation in R&D policy," Research Policy, Elsevier, vol. 27(6), pages 639-654, September. [Downloadable!] (restricted)
  9. Rebecca Henderson & Iain Cockburn, . "Scale, Scope and Spillovers: The Determinants of Research Productivity in Drug Discovery," Working Papers ec25/94, Department of Economics, University of Lancaster.
    Other versions:
  10. Pavitt, Keith, 1998. "The inevitable limits of EU R&D funding," Research Policy, Elsevier, vol. 27(6), pages 559-568, September. [Downloadable!] (restricted)
Full references

Cited by:
(explanations, Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.)

  1. Frances Ruane & Xiaoheng Zhang, 2007. "Where do MNEs Expand Production: Location Choices of the Pharmaceutical Industry in Europe after 1992," Papers WP211, Economic and Social Research Institute (ESRI). [Downloadable!]
  2. Owen-Smith, Jason & Riccaboni, Massimo & Pammolli, Fabio & Powell, Walter W., 2002. "A Comparison of U.S. and European University-Industry Relations in the Life Sciences," MPRA Paper 15963, University Library of Munich, Germany. [Downloadable!]
    Other versions:
  3. Heneric, Oliver & Engel, Dirk & Champenois, Claire, 2004. "The Birth of German Biotechnology Industry : Did Venture Capital run the Show?," ZEW Discussion Papers 04-09, ZEW - Zentrum für Europäische Wirtschaftsforschung / Center for European Economic Research. [Downloadable!]
  4. Pammolli, Fabio & Riccaboni, Massimo, 2004. "Market Structure and Drug Innovation," MPRA Paper 16212, University Library of Munich, Germany. [Downloadable!]
  5. Bernard Guilhon, 2004. "Markets for knowledge: problems, scope, and economic implications," Economics of Innovation and New Technology, Taylor and Francis Journals, vol. 13(2), pages 165-181, March. [Downloadable!] (restricted)
  6. Frances Ruane & Xiaoheng Zhang, 2007. "Location Choices of the Pharmaceutical Industry in Europe after 1992," The Institute for International Integration Studies Discussion Paper Series iiisdp220, IIIS. [Downloadable!]
  7. Herrmann, Andrea M., 2008. "Choosing and Successfully Sustaining Competitive Strategies in the European Pharmaceutical Industry," MPIfG Discussion and Working Papers 9, Max Planck Institute for the Study of Societies. [Downloadable!]
  8. Antonio Cabrales, 2003. "Pharmaceutical Generics, Vertical Product Differentiation, and Public Policy," Working Papers, Research Center on Health and Economics 662, Department of Economics and Business, Universitat Pompeu Fabra. [Downloadable!]
    Other versions:
  9. Dirk Engel & Claire Champenois & Oliver Heneric, 2004. "The Birth of German Biotechnology Industry – Did Venture Capital run the show?," RWI Discussion Papers 0016, Rheinisch-Westfälisches Institut für Wirtschaftsforschung. [Downloadable!]
  10. Antonio Cabrales & Sergi Jiménez-Martín, 2007. "The Determinants of Pricing in Pharmaceuticals: Are U.S. Prices Really Higher than Those of Canada?," UFAE and IAE Working Papers 697.07, Unitat de Fonaments de l'Anàlisi Econòmica (UAB) and Institut d'Anàlisi Econòmica (CSIC). [Downloadable!]
    Other versions:
  11. Antonio Cabrales & Sergi Jiménez-Martín, 2008. "The Determinants of Pricing in Pharmaceuticals: Are U.S. prices really so high?," Working Papers 2008-18, FEDEA. [Downloadable!]
  12. Archibugi, Daniele & .Kim Bizzarri, 2004. "Committing to Vaccine R&D: A Global Science Policy Priority/Comprometerse en la investigación y desarrollo de vacunas: una prioridad de la política científica global," Estudios de Economía Aplicada, Estudios de Economía Aplicada, vol. 22, pages 251-271, Agosto. [Downloadable!] (restricted)
  13. Klaus Desmet & Clara Eugenia García & Praveen Kujal & Félix Lobo, 2003. "Implementing R&D Policies: An Analysis Of Spain’S Pharmaceutical Research Program," Economics Working Papers we035923, Universidad Carlos III, Departamento de Economía. [Downloadable!]
    Other versions:
  14. Franco Malerba & Luigi Orsenigo, 2000. "Towards a History Friendly Model of Innovation, Market Structure and Regulation in the Dynamics of the Pharmaceutical Industry: the Age of Random Screening," CESPRI Working Papers 124, CESPRI, Centre for Research on Innovation and Internationalisation, Universita' Bocconi, Milano, Italy, revised Jan 2001. [Downloadable!]
Statistics
Access and download statistics

Did you know? About 1000 journals are listed on RePEc.

This page was last updated on 2009-11-30.


This information is provided to you by IDEAS at the Department of Economics, College of Liberal Arts and Sciences, University of Connecticut using RePEc data on a server sponsored by the Society for Economic Dynamics.